NHS rationing means you have to weigh same as a sumo wrestler to get weight loss jabs

The NHS has launched an urgent appeal for blood donors, citing concerns over the growing demand for blood treatments for patients with sickle cell disease. According to health experts, the NHS is currently meeting only about half of the blood requirements for those undergoing treatment for the condition. NHS Blood and Transplant (NHSBT) is calling for more donors, especially those of Black heritage, as an estimated 16,000 additional volunteers are needed to meet the demand. This comes amid the 20th anniversary of the nationwide rollout of newborn sickle cell screening in England. Sickle cell disease is an inherited blood condition that causes the body to produce abnormally shaped red blood cells, which can restrict blood flow. The illness is more common among individuals with African or Caribbean ancestry. Symptoms include pain, fatigue, and painful swelling in the hands and feet, with treatment involving medication and regular blood transfusions. Black donors are crucial for treating sickle cell patients because they are significantly more likely to provide a compatible blood match. This is largely due to the fact that they are ten times more likely than white individuals to possess the Ro blood subtype, which is essential for treating the disorder. Gerry Gogarty, director of blood supply at NHSBT, emphasized the importance of increasing the donor base, noting that while the number of Black donors has risen by 120% over the past decade, more are needed to meet current demands. Yann-Elie Asket, a 22-year-old politics student in Greenwich, joined the call to donate blood after losing his cousin to sickle cell disease. He described the impact of his cousin's death on his family and highlighted the importance of blood donation in helping others. Iyamide Thomas, of the Sickle Cell Society and NHS engagement lead for the screening program, noted that the past 20 years have brought significant progress in managing the condition through early diagnosis and improved treatment options. Separately, the NHS faces challenges in providing weight loss medications to those who need them. Currently, only the most severely obese individuals qualify for prescriptions of drugs like Mounjaro and Wegovy, which suppress appetite. Professor John Deanfield, a leading expert in these drugs, pointed out that the average BMI of patients receiving these medications is 47, comparable to that of a sumo wrestler. He criticized the approach, stating that it is counterproductive to wait until individuals develop severe health complications before offering treatment. The NHS is prioritizing the most critically obese patients due to limited resources for personalized support services necessary for effective weight management. Trials suggest that these drugs can help individuals lose up to a fifth of their body weight and reduce the risk of several chronic conditions. However, the NHS is projected to take 12 years to roll out Mounjaro to the 3.4 million people eligible for the drug. Approximately 2.5 million Britons are currently using weight loss jabs privately, though many discontinue use due to financial constraints. Experts argue that restricting access to these medications is a false economy, emphasizing the potential long-term savings from preventing obesity-related illnesses. The NHS is exploring whether remote support, such as through apps, can adequately assist users in making necessary lifestyle changes. Without proper guidance, users risk regaining lost weight and failing to maintain muscle and bone density.